secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2022-06-14T23:59:59+00:00
Accession:  0001193125-22-173902
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK adopts Executive Change of Control Plan; stockholders elect directors, ratify KPMG
--------------------------------------------------------------------------------

- Board approved Executive Change of Control Plan providing 50% time-based equity vesting upon a change of control.
- Plan includes severance: 12 months salary plus target/actual bonus, COBRA coverage, and full equity vesting for qualifying terminations after a change of control.
- Stockholders re-elected Peter Behner, Jennifer Buell, and Ulf Wiinberg as Class I directors at June 8 annual meeting.
- Proposal to ratify KPMG as independent auditor for FY2022 approved with 28.1M votes for.
- Plan also includes non-compete and non-solicitation covenants for participating executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000119312522173902/0001193125-22-173902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000119312522173902/d364118d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-173902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer